HybO2 has been treating Long COVID sufferers with significant results. This is backed up by a detailed scientific randomised controlled trial on the improvements HBOT has on neurocognitive functions and symptoms of post-COVID conditions.
Experiencing a bout of COVID-19 is bad enough. But for far too many people, surviving COVID leads to lingering neurocognitive, neuropsychological, or physical symptoms called long COVID, also known as post-COVID-19 syndrome or COVID-Brain. Of the over 40% of Americans who have had COVID-19, an estimated 19% of them meet the criteria for long COVID, according to the Household Pulse Survey. This means that over 25 million people are still struggling with symptoms related to infection with SARS-CoV-2. A 2022 brain-imaging study in Nature Medicine has identified an astounding 62 symptoms related to long COVID. These symptoms include but are not limited to:
HybO2 has been treating Long COVID sufferers with significant results. This is backed up by a detailed scientific randomised controlled trial on the improvements Hyperbaric Oxygen Therapy (HBOT) has on neurocognitive functions and symptoms of post-COVID conditions.
To read other HybO2 Long COVID related articles see https://www.hybo2.com/hyperbaric-oxygen-therapy-long-covid/
Authors: Shani Zilberman‑Itskovich, Merav Catalogna1,4, Efrat Sasson1, Karin Elman‑Shina, Amir Hadanny, Erez Lang, Shachar Finci1, Nir Polak, Gregory Fishlev, Calanit Korin, Ran Shorer, Yoav Parag, Marina Sova1 & Shai Efrati1.
Further reading: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276805/
